Literature DB >> 19497082

Very early mortality in patients starting antiretroviral treatment at primary health centres in rural Malawi.

Rony Zachariah1, Katie Harries, Massaquoi Moses, Marcel Manzi, Arnould Line, Beatrice Mwagomba, Anthony D Harries.   

Abstract

OBJECTIVES: To report on the cumulative proportion of deaths occurring within 3 months of starting antiretroviral treatment (ART) and to identify factors associated with such deaths, among adults at primary health centres in a rural district of Malawi.
METHODS: Retrospective cohort study: from June 2006 to April 2008, deaths occurring over a 3-month period were determined and risk factors examined.
RESULTS: A total of 2316 adults (706 men and 1610 women; median age 35 years) were included in the analysis and followed up for a total of 1588 person-years (PY); 277 (12%) people died, of whom 206 (74%) people died within 3 months of initiating ART (cumulative incidence: 13.0; 95% confidence interval: 11.3-14.8 per 100 PY of follow-up). Significant risk factors associated with early deaths included male sex, WHO stage 4 disease, oesophageal or persistent oral candidiasis and unexplained presumed or measured weight loss >10%. One in every 3 patients who either died or was lost to follow up had unexplained weight loss >10%, and survival in this group was significantly different from patients without this condition.
CONCLUSIONS: Seven in 10 individuals initiating ART at primary health centres die early. Specific groups of patients are at higher risk of such mortality and should receive priority attention, care and support.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19497082     DOI: 10.1111/j.1365-3156.2009.02291.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  24 in total

1.  Treatment outcomes after 7 years of public-sector HIV treatment.

Authors:  Matthew P Fox; Kate Shearer; Mhairi Maskew; William Macleod; Pappie Majuba; Patrick Macphail; Ian Sanne
Journal:  AIDS       Date:  2012-09-10       Impact factor: 4.177

2.  Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007.

Authors:  Morna Cornell; Anna Grimsrud; Lara Fairall; Matthew P Fox; Gilles van Cutsem; Janet Giddy; Robin Wood; Hans Prozesky; Lerato Mohapi; Claire Graber; Matthias Egger; Andrew Boulle; Landon Myer
Journal:  AIDS       Date:  2010-09-10       Impact factor: 4.177

3.  Changing predictors of mortality over time from cART start: implications for care.

Authors:  Christopher J Hoffmann; Katherine L Fielding; Victoria Johnston; Salome Charalambous; Craig Innes; Richard D Moore; Richard E Chaisson; Alison D Grant; Gavin J Churchyard
Journal:  J Acquir Immune Defic Syndr       Date:  2011-11-01       Impact factor: 3.731

4.  Neuropsychiatric and socioeconomic status impact antiretroviral adherence and mortality in rural Zambia.

Authors:  Gretchen L Birbeck; Michelle P Kvalsund; Peter A Byers; Richard Bradbury; Charles Mang'ombe; Natalie Organek; Trevor Kaile; Alex M Sinyama; Sylvester S Sinyangwe; Kennedy Malama; Costantine Malama
Journal:  Am J Trop Med Hyg       Date:  2011-10       Impact factor: 2.345

5.  Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa.

Authors:  Katharina Kranzer; Jennifer Zeinecker; Philip Ginsberg; Catherine Orrell; Nosindiso N Kalawe; Stephen D Lawn; Linda-Gail Bekker; Robin Wood
Journal:  PLoS One       Date:  2010-11-02       Impact factor: 3.240

6.  What happens to ART-eligible patients who do not start ART? Dropout between screening and ART initiation: a cohort study in Karonga, Malawi.

Authors:  Nuala McGrath; Judith R Glynn; Jacqueline Saul; Katharina Kranzer; Andreas Jahn; Frank Mwaungulu; Msenga H C Ngwira; Hazzie Mvula; Fipson Munthali; Venance Mwinuka; Lorren Mwaungulu; Paul E M Fine; Amelia C Crampin
Journal:  BMC Public Health       Date:  2010-10-12       Impact factor: 3.295

7.  Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors.

Authors:  Katharina Kranzer; James J Lewis; Nathan Ford; Jennifer Zeinecker; Catherine Orrell; Stephen D Lawn; Linda-Gail Bekker; Robin Wood
Journal:  J Acquir Immune Defic Syndr       Date:  2010-11       Impact factor: 3.731

8.  The role of host gender in the pathogenesis of Cryptococcus neoformans infections.

Authors:  Erin E McClelland; Letizia M Hobbs; Johanna Rivera; Arturo Casadevall; Wayne K Potts; Jennifer M Smith; Jeramia J Ory
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

9.  Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.

Authors:  A Sarah Walker; Andrew J Prendergast; Peter Mugyenyi; Paula Munderi; James Hakim; Addy Kekitiinwa; Elly Katabira; Charles F Gilks; Cissy Kityo; Patricia Nahirya-Ntege; Kusum Nathoo; Diana M Gibb
Journal:  Clin Infect Dis       Date:  2012-09-12       Impact factor: 9.079

10.  Who starts? Factors associated with starting antiretroviral therapy among eligible patients in two, public HIV clinics in Lilongwe, Malawi.

Authors:  Caryl Feldacker; Derek Johnson; Mina Hosseinipour; Sam Phiri; Hannock Tweya
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.